Bio-Techne TECH Business Segments
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Diagnostics And Spatial Biology | $85.59M+5.4% | $81.18M+2.2% | $79.46M-11.4% | $89.71M+0.5% | $89.23M+6.1% | |
| Protein Sciences | $226.15M+5.1% | $215.08M+6.4% | $202.19M-10.7% | $226.47M-0.5% | $227.69M+7.6% | |
| Operating Income by Business | ||||||
| Diagnostics And Spatial Biology | $10.32M+22.4% | $8.43M-5.0% | $8.88M+64.9% | $5.38M-36.1% | $8.42M+160% | |
| Protein Sciences | $100M+18.2% | $84.62M+8.9% | $77.71M-21.3% | $98.79M-4.9% | $103.91M+19.3% | |
| Selling General And Administrative Expense by Business | ||||||
| Diagnostics And Spatial Biology | $27.62M+0.1% | $27.6M-0.9% | $27.85M-18.3% | $34.1M+2.0% | $33.42M-4.7% | |
| Protein Sciences | $57.91M-1.8% | $58.99M-1.3% | $59.77M+1.9% | $58.64M+5.1% | $55.8M-2.9% | |
| Cost of Goods Sold by Business | ||||||
| Diagnostics And Spatial Biology | $38.65M+6.0% | $36.47M+8.1% | $33.74M-14.7% | $39.53M+6.3% | $37.19M+4.5% | |
| Protein Sciences | $53.79M-5.7% | $57.03M+12.9% | $50.52M-7.5% | $54.61M+2.7% | $53.19M+2.4% | |
| Restructuring Charges by Business | ||||||
| Corporate | $688K+71.6% | $401K-45.8% | $740K+52.0% | $487K+67.4% | $291K+54.0% | |
| Diagnostics And Spatial Biology | $27K— | —— | -$6.79M-108% | $82.68M— | $0+100% | |
| Protein Sciences | $2.12M-26.7% | $2.9M-9.8% | $3.21M+310% | $783K+507% | $129K-95.4% | |
| Research And Development Expense Excluding Acquired In Process Cost by Business | ||||||
| Diagnostics And Spatial Biology | $9M+3.7% | $8.68M-3.5% | $8.99M-15.9% | $10.69M+4.8% | $10.2M-0.4% | |
| Protein Sciences | $14.45M0.0% | $14.45M+1.8% | $14.19M-1.7% | $14.44M-2.3% | $14.78M-1.7% | |
| Goodwill by Business | ||||||
| Diagnostics And Spatial Biology | $553.62M-0.2% | $554.67M+0.1% | $554.11M0.0% | $554.16M+1.2% | $547.5M+0.5% | |
| Protein Sciences | $424.18M-0.4% | $425.89M+0.3% | $424.8M-0.5% | $426.78M+1.3% | $421.12M+0.3% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Diagnostics And Spatial Biology | -$1.05M-288% | $559K+1,265% | -$48K-100% | $11.15M+313% | $2.7M+124% | |
| Protein Sciences | -$1.71M— | —— | -$1.98M-135% | $5.66M+333% | $1.31M+120% | |
| Revenue by Product | ||||||
| Consumables | $257.34M+9.3% | $235.44M+1.7% | $231.6M-8.4% | $252.94M-1.9% | $257.79M+11.7% | |
| Instruments | $27.66M-6.6% | $29.61M+35.6% | $21.83M-24.5% | $28.9M+10.7% | $26.11M-15.4% | |
| Royalty | $4.97M-41.7% | $8.51M+50.8% | $5.65M+2.6% | $5.51M+9.2% | $5.04M-37.8% | |
| Service | $21.45M-3.9% | $22.32M-18.8% | $27.48M-7.2% | $29.62M+8.7% | $27.25M-0.4% | |
| Revenue by Geography | ||||||
| APAC Excluding Greater China | $21.82M-4.1% | $22.74M+18.8% | $19.15M+1.4% | $18.89M-11.1% | $21.25M+11.8% | |
| CN | $26.01M-1.3% | $26.35M+6.3% | $24.79M-7.9% | $26.91M+9.9% | $24.48M-1.1% | |
| EMEA Excluding UK | $73.45M-2.5% | $75.35M+15.7% | $65.13M-7.4% | $70.35M+5.8% | $66.5M-5.5% | |
| GB | $14.89M+8.5% | $13.73M+4.0% | $13.21M-10.7% | $14.79M+15.1% | $12.85M-3.0% | |
| Rest Of World | $7.77M-30.3% | $11.15M+23.2% | $9.05M-6.2% | $9.65M+5.1% | $9.18M-5.6% | |
| US | $167.48M+14.3% | $146.56M-5.6% | $155.24M-12.0% | $176.39M-3.0% | $181.92M+13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Techne break its business down?
- Bio-Techne (TECH) reports revenue by business across 2 parts — Diagnostics And Spatial Biology and Protein Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Techne's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Techne's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
